Truist Financial Corp Mersana Therapeutics, Inc. Transaction History

Truist Financial Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 22, 2022	SELL	$3.74 - $6.63 $62,458 - $110,721	-16,700 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$13.28 - $18.07 $66,400 - $90,350	5,000 Added 42.74%	16,700 $227,000
Q4 2020 Nov 19, 2021	SELL	$16.84 - $27.59 $64,951 - $106,414	-3,857 Reduced 24.79%	11,700 $311,000
Q4 2020 Feb 18, 2021	BUY	$16.84 - $27.59 $64,951 - $106,414	3,857 Added 32.97%	15,557 $414,000
Q3 2020 Nov 13, 2020	BUY	$16.2 - $25.7 $189,540 - $300,690	11,700 New	11,700 $218,000

136

101M

77.2K

453K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $44.7M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.